The abuse and dependence potential of Gabapentin Capsules has not been evaluated in human studies.
A lethal dose of gabapentin was not identified in mice and rats receiving single oral doses as high as 8000 mg/kg. Signs of acute toxicity in animals included ataxia, labored breathing, ptosis, sedation, hypoactivity, or excitation.
Acute oral overdoses of Gabapentin Capsules up to 49 grams have been reported. In these cases, double vision, slurred speech, drowsiness, lethargy and diarrhea were observed. All patients recovered with supportive care.
Gabapentin can be removed by hemodialysis. Although hemodialysis has not been performed in the few overdose cases reported, it may be indicated by the patient’s clinical state or in patients with significant renal impairment.
Gabapentin Capsules is given orally with or without food.
If Gabapentin Capsules dose is reduced, discontinued or substituted with an alternative medication, this should be done gradually over a minimum of 1 week (a longer period may be needed at the discretion of the prescriber).
In adults with postherpetic neuralgia, Gabapentin Capsules therapy may be initiated as a single 300-mg dose on Day 1, 600 mg/day on Day 2 (divided BID), and 900 mg/day on Day 3 (divided TID). The dose can subsequently be titrated up as needed for pain relief to a daily dose of 1800 mg (divided TID). In clinical studies, efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day with comparable effects across the dose range. Additional benefit of using doses greater than 1800 mg/day was not demonstrated.
Gabapentin Capsules is recommended for add-on therapy in patients 3 years of age and older. Effectiveness in pediatric patients below the age of 3 years has not been established.
Patients >12 years of age: The effective dose of Gabapentin Capsules is 900 to 1800 mg/day and given in divided doses (three times a day) using 300 or 400 mg capsules. The starting dose is 300 mg three times a day. If necessary, the dose may be increased using 300 or 400 mg capsules three times a day up to 1800 mg/day. Dosages up to 2400 mg/day have been well tolerated in long-term clinical studies. Doses of 3600 mg/day have also been administered to a small number of patients for a relatively short duration, and have been well tolerated. The maximum time between doses in the TID schedule should not exceed 12 hours.
Pediatric Patients Age 3–12 years: The starting dose should range from 10-15 mg/kg/day in 3 divided doses, and the effective dose reached by upward titration over a period of approximately 3 days. The effective dose of Gabapentin Capsules in patients 5 years of age and older is 25–35 mg/kg/day and given in divided doses (three times a day). The effective dose in pediatric patients ages 3 and 4 years is 40 mg/kg/day and given in divided doses (three times a day) (see CLINICAL PHARMACOLOGY, Pediatrics.) Dosages up to 50 mg/kg/day have been well-tolerated in a long-term clinical study. The maximum time interval between doses should not exceed 12 hours.
It is not necessary to monitor gabapentin plasma concentrations to optimize Gabapentin Capsules therapy. Further, because there are no significant pharmacokinetic interactions among Gabapentin Capsules and other commonly used antiepileptic drugs, the addition of Gabapentin Capsules does not alter the plasma levels of these drugs appreciably.
If Gabapentin Capsules is discontinued and/or an alternate anticonvulsant medication is added to the therapy, this should be done gradually over a minimum of 1 week.
Dosage in Renal Impairment
Creatinine clearance is difficult to measure in outpatients. In patients with stable renal function, creatinine clearance (CCr ) can be reasonably well estimated using the equation of Cockcroft and Gault:
for females CCr =(0.85)(140 age)(weight)/[(72)(SCr )]for males CCr =(140 age)(weight)/[(72)(SCr )]
where age is in years, weight is in kilograms and SCr is serum creatinine in mg/dL.
Dosage adjustment in patients ≥ 12 years of age with compromised renal function or undergoing hemodialysis is recommended as follows (see dosing recommendations above for effective doses in each indication).
|Renal Function Creatinine Clearance (mL/min)||Total Daily Dose Range (mg/day)||Dose Regimen (mg)|
|a For patients with creatinine clearance <15 mL/min, reduce daily dose in proportion to creatinine clearance (e.g., patients with a creatinine clearance of 7.5 mL/min should receive one-half the daily dose that patients with a creatinine clearance of 15 mL/min receive).|
|b Patients on hemodialysis should receive maintenance doses based on estimates of creatinine clearance as indicated in the upper portion of the table and a supplemental post-hemodialysis dose administered after each 4 hours of hemodialysis as indicated in the lower portion of the table.|
|≥60||900-3600||300 TID||400 TID||600 TID||800 TID||1200 TID|
|>30-59||400-1400||200 BID||300 BID||400 BID||500 BID||700 BID|
|>15-29||200-700||200 QD||300 QD||400 QD||500 QD||700 QD|
|15a||100-300||100 QD||125 QD||150 QD||200 QD||300 QD|
|Post-Hemodialysis Supplemental Dose (mg)b|
The use of Gabapentin Capsules in patients <12 years of age with compromised renal function has not been studied.
Dosage in Elderly
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and dose should be adjusted based on creatinine clearance values in these patients.
Gabapetin Capsules are available as follows:
100 mg capsules: White-White, opaque hard gelatin capsules printed with “IP 101” on both cap and body.
300 mg capsules: Buff-Buff, opaque hard gelatin capsules printed with “IP 102” on both cap and body.
400 mg capsules: Light caramel-Light caramel, opaque hard gelatin capsules printed with “IP 103” on both cap and body.
They are supplied by Keltman Pharmaceuticals Inc. as follows:
|NDC||Strength||Quantity/Form||Color||Source Prod. Code|
|68387-420-30||100 mg||30 Capsules in a Plastic Bottle||WHITE||53746-101|
|68387-420-90||100 mg||90 Capsules in a Plastic Bottle||WHITE||53746-101|
|68387-420-12||100 mg||120 Capsules in a Plastic Bottle||WHITE||53746-101|
|68387-410-30||300 mg||30 Capsules in a Plastic Bottle||Buff-Buff||53746-102|
|68387-410-60||300 mg||60 Capsules in a Plastic Bottle||Buff-Buff||53746-102|
|68387-410-90||300 mg||90 Capsules in a Plastic Bottle||Buff-Buff||53746-102|
|68387-410-18||300 mg||180 Capsules in a Plastic Bottle||Buff-Buff||53746-102|
|68387-404-60||400 mg||60 Capsules in a Plastic Bottle||Light caramel-Light caramel||53746-103|
|68387-404-90||400 mg||90 Capsules in a Plastic Bottle||Light caramel-Light caramel||53746-103|
|68387-404-12||400 mg||120 Capsules in a Plastic Bottle||Light caramel-Light caramel||53746-103|
Store at 20 to 25°C (68 to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Amneal Pharmaceuticals of NY
Hauppauge, NY 11788
Glasgow, KY 42141
This Product was Repackaged By Sandhills Packaging for:
Keltman Pharmaceuticals Inc.
1 Lakeland Square, Suite A
Flowood, MS 39232
|GABAPENTIN gabapentin capsule|
|GABAPENTIN gabapentin capsule|
|GABAPENTIN gabapentin capsule|
|Labeler — Keltman Pharmaceuticals Inc. (362861077)|
|Keltman Pharmaceuticals Inc.||362861077||repack, relabel|
Revised: 02/2011 Keltman Pharmaceuticals Inc.
RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.